NASDAQ · Biotechnology

Madrigal Pharmaceuticals, Inc. (MDGL) Stock

$476.91 -2.22% NASDAQ: MDGL Healthcare

Valuation

MetricValue
Price$476.91
Market Cap$11.02B
P/E Ratio-39.10
P/B Ratio28.05
P/S Ratio9.07
EPS (TTM)$-12.85
52-Week High$615.00
52-Week Low$393.61
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-56.65%
ROA-26.12%
ROCE-37.06%
Gross Margin93.07%
Operating Margin-27.68%
Net Margin-25.32%
Debt/Equity0.66
Current Ratio4.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$180.0M$958.0M
Operating Profit$-242.0M$-294.0M$-380.0M$-498.0M$-300.0M
Net Profit$-242.0M$-295.0M$-374.0M$-466.0M$-288.0M
EPS$-14.63$-17.23$-19.99$-21.90$-12.85
Op Margin———-276.4%-31.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$273.0M$363.0M$641.0M$1.0B$1.3B
Total Liabilities$77.0M$165.0M$235.0M$288.0M$657.0M
Cash$36.0M$332.0M$100.0M$100.0M$199.0M
Borrowings$1.0M$50.0M$117.0M$120.0M$354.0M

Latest News

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 GlobeNewswire · Jul 16, 2026 MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug Stocktwits · Jul 13, 2026 Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says MT Newswires · Jul 13, 2026 Sector Update: Health Care Stocks Lower Early Monday MT Newswires · Jul 13, 2026 Madrigal Pharmaceuticals Expands Rezdiffra Patent Protection With Three New Patents MT Newswires · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-184.0M$-225.0M$-324.0M$-456.0M$-190.0M
Investing Cash Flow$-5.0M$206.0M$-504.0M$-276.0M$32.0M
Financing Cash Flow$1.0M$8.0M$270.0M$338.0M$0
Net Cash Flow$-18.0M$295.0M$-232.0M$5.0M$99.0M
Free Cash Flow$-184.0M$-225.0M$-326.0M$-457.0M$-190.0M

Valuation & Return Ratios

MetricValue
PEG Ratio113.26
EV / EBITDA-39.16
FCF Yield-1.77%
Quick Ratio2.94
Interest Coverage-20.64
Return 1Y12.24%
Return 3Y252.39%
Return 5Y513.81%

Ownership

Insiders Held5.68%
Institutions Held106.99%
Institutions Float Held113.44%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP2,141,7012026-03-31
Janus Henderson Group PLC2,018,6472026-03-31
RTW Investments LP1,993,6872026-03-31
Avoro Capital Advisors LLC1,818,1812026-03-31
Blackrock Inc.1,559,9652026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALTAltimmune, Inc. $2.60 -2.26% -3.42 $505.63M 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%
MAZEMaze Therapeutics, Inc. $25.88 -1.41% -9.65 $1.43B 0.00%
NAMSNewAmsterdam Pharma Company N.V. $21.26 -3.93% -10.64 $2.49B 0.00%
SGMTSagimet Biosciences Inc. - Series A $8.92 +0.45% -7.14 $290.63M 0.00%

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is led by CEO William J. Sibold, employs 915 people, headquartered in West Conshohocken, US, publicly traded since 2007.

Madrigal Pharmaceuticals, Inc. (MDGL) stock trades at $476.91 with a market capitalization of $11.02B. The stock is valued at a price-to-earnings (P/E) ratio of -39.10, price-to-book of 28.05, price-to-sales of 9.07. Over the past 52 weeks the stock has ranged between $393.61 and $615.00, and currently trades 22.5% below its 52-week high.

On profitability, Madrigal Pharmaceuticals, Inc. generates a return on equity (ROE) of -56.65%, return on capital employed of -37.06%, an operating margin of -27.68%, a net profit margin of -25.32%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides